Hypertension, is a common condition that is characterized by abnormally high blood pressure in blood vessel. It is a significant risk factor for cardiovascular mortality and morbidity but is not a disease in and of itself. Amlodipine besylate, Telmisartan, and Indapamide, a more recent combination that has been approved by the National Institutes of Health for a phase 3 clinical trial, is beneficial in reducing hypertension. Amlodipine besylate is a calcium channel blocker, Telmisartan is an angiotensin II receptor antagonist and Indapamide is a thiazide diuretic. Different analytical methods using different techniques such as liquid chromatography, high-performance liquid chromatography, high-performance thin-layer chromatography, gas chromatography, spectrophotometry, spectrofluorimetric methods coupled with ultraviolet, fluorescence, mass, or tandem mass spectrometry for estimation of this individual drug and in combination with other drug have been reported. Therefore, this review summarizes the main analytical aspects reported in literature regarding not only simultaneous estimation but also stability-indicating methods for the analysis of proposed drugs in bulk and pharmaceutical dosage forms. Thus, this review gathers, for the first time, important background information on all analytical methods that have been developed and applied for the determination of Amlodipine Besylate, Telmisartan, and Indapamide. Furthermore, the reported methods have been also evaluated by greenest assessment tools, AGREE providing a comprehensive overview of various feature of analytical methods defining sustainability. Based on AGREE, total 134 methods including UV, HPLC and HPTLC were evaluated
